Metastatic Castration-resistant Prostate Cancer (mCRPC) Clinical Trials in Wuhan, Hubei
2 recruitingWuhan, Hubei, China
Showing 1–2 of 2 trials
Recruiting
Phase 3
A Study of Opevesostat (MK-5684) Versus Alternative Next-generation Hormonal Agent (NHA) in Metastatic Castration-resistant Prostate Cancer (mCRPC) Post One NHA (MK-5684-004)
Metastatic Castration-resistant Prostate Cancer (mCRPC)Prostatic Neoplasms
Merck Sharp & Dohme LLC1,314 enrolled324 locationsNCT06136650
Recruiting
Phase 2
A Phase II Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of YL201 in Patients With mCRPC
Metastatic Castration-resistant Prostate Cancer (mCRPC)
MediLink Therapeutics (Suzhou) Co., Ltd.100 enrolled24 locationsNCT06241846